Dendritic cells and cytokines in immune rejection of cancer.
Dendritic cells (DCs) play a crucial role in linking innate and adaptive immunity and, thus, in the generation of a protective immune response against both infectious diseases and tumors. The ability of DCs to prime and expand an immune response is regulated by signals acting through soluble mediators, mainly cytokines and chemokines. Understanding how cytokines influence DC functions and orchestrate the interactions of DCs with other immune cells is strictly instrumental to the progress in cancer immunotherapy. Herein, we will illustrate how certain cytokines and immune stimulating molecules can induce and sustain the antitumor immune response by acting on DCs. We will also discuss these cytokine-DC interactions in the light of clinical results in cancer patients.
Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy. maria.ferrantini@iss.it
Maria
M
Ferrantini
Imerio
I
Capone
Filippo
F
Belardelli
D000276:Adjuvants, Immunologic / Q000502:physiology; D000634:Aminoquinolines / Q000627:therapeutic use; D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000627:therapeutic use; D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D018899:CpG Islands / Q000502:physiology; D016207:Cytokines / Q000502:physiology*; D003713:Dendritic Cells / Q000276:immunology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D007167:Immunotherapy; D016898:Interferon-alpha / Q000627:therapeutic use; D009369:Neoplasms / Q000276:immunology* / Q000517:prevention & control; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use; D051217:Toll-Like Receptor 9 / Q000819:agonists
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000951:Antigens, Neoplasm; C408982:CPG-oligonucleotide; D019496:Cancer Vaccines; D016207:Cytokines; D016898:Interferon-alpha; D009838:Oligodeoxyribonucleotides; D051217:Toll-Like Receptor 9; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000077271:Imiquimod